Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

55.09 -4.07 (-6.89%)
Streaming Delayed Price Updated: 12:03 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
(ACLX) - Analyzing Arcellx's Short Interest
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
Via Benzinga
14 Analysts Have This To Say About Arcellx
Via Benzinga
Analyst Expectations For Arcellx's Future
Via Benzinga
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
From Arcellx, Inc.
Via Business Wire
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
Via Benzinga
4 Analysts Assess Arcellx: What You Need To Know
Via Benzinga
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
Via Benzinga
Decoding 8 Analyst Evaluations For Arcellx
Via Benzinga
The Latest Analyst Ratings For Arcellx
Via Benzinga
Expert Ratings For Arcellx
Via Benzinga
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Analyst Expectations For Arcellx's Future
Via Benzinga
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.